Triple Negative Breast Cancer Study Tests Way of Monitoring Metastasis Using Blood Samples

Triple Negative Breast Cancer Study Tests Way of Monitoring Metastasis Using Blood Samples
Cynvenio Biosystems, Inc. recognized the recent Triple Negative Breast Cancer Day by announcing the launch of a clinical trial in women with triple negative breast cancer (TNBC), a breast cancer subtype marked by negative estrogen-, progesterone-, and Her-2–receptor gene expression, that will evaluate the company’s non-invasive liquid biopsy technology to monitor patients and identify early metastasis. The pilot study is now recruiting participants with previously treated, non-metastatic TNBC. Cynvenio Biosystems' proprietary LiquidBiopsy is a multi-template technology for the molecular characterization of tumor cells from a standard blood draw. “Currently there is no effective way to monitor women who have completed standard therapy for TNBC and who remain at high risk of recurrence and metastases,” Paul Y. Song, Cynvenio’s CMO, said in a 
Subscribe or to access all post and page content.